The present invention relates to the treatment of haemophilia. More specifically, the invention relates to a new method of inducing an immune tolerance against at least one blood factor used to treat haemophilia through the epicutaneous route by application of a skin patch device comprising a blood factor in order to continue haemophilia treatment. The present invention also relates to the skin patch device containing Factor VIII.
